Leland Stanford Junior University

The United States Government As Represented by the Department of Veterans Affairs

Johns Hopkins University

Intermune, Inc.

Mark R Nicolls

Jayakumar Rajadas

Xinguo Jiang

Wen A Tian

Geoffrey C Gurtner

Gregg L Semenza

Gundeep Dhillon

Alan J Cohen

Karl Kossen

Mohammed Inayathullah Nazir Ahmed

Stanley G Rockson

JooChuan Ang

Jeanna Kim

Preetha Jothimuthu

Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. suspended in a carrier compatible with the tissue of interest, is topically applied to the surface of tissues at the site of anastomosis. The nanoparticles are comprised of the active agent and a pharmaceutically acceptable stabilizer.

HIF-1 modulator paint formulation and uses thereof

Improved electrochemical impedance spectroscopy assays are provided by electrodepositing metallic nanoparticles onto the working electrode for electrochemical impedance spectroscopy. The metallic nanoparticles provide improved assay sensitivity. Electrodeposition of the metallic nanoparticles firmly affixes them to the working electrode, thereby making it easier to clean the working electrode from one assay to the next assay without undesirably removing the metallic nanoparticles.

Nanogrid electrochemical sensor for detection of biochemical species by electrochemical impedance spectroscopy

Provided are therapeutic methods for treating a patient with lymphedema, or prophylactically treating an individual susceptible to lymphedema, by inhibiting synthesis activity of leukotriene B.

LTB4 inhibition to prevent and treat human lymphedema

Pulmonary arterial hypertension (PAH) can be prevented in persons susceptible to the diseases and PAH patients can be treated by administering an effective dose of a leukotriene inhibitor. Suitable inhibitors include leukotriene Ahydrolase (LTAH) inhibitors, leukotriene Breceptor (BLT1/BLT2) antagonists, 5-lipoxygenase (5-LO) inhibitors, and 5-lipoxgygenase activating protein (FLAP) inhibitors.

Treatment of pulmonary arterial hypertension with leukotriene inhibitors

Formulations and methods are provided for improving the function, i.e. clinical outcome, of solid organ transplants. Lung transplantation is of particular interest. In the methods of the invention, a nanoparticle formulation comprising an effective dose of an iron chelator active agent in nanoparticle form, including without limitation, deferoxamine (DFO), deferasirox (DFX), and deferiprone (DFP), etc. is topically applied to the surface of tissues during episodes of graft rejection.

Iron chelators and use thereof for reducing transplant failure during rejection episodes

The disclosure relates to methods of preserving or improving microvascular integrity in a patient in need thereof comprising administering pirfenidone therapy to the patient.

Methods of improving microvascular integrity

Pulmonary arterial hypertension (PAH) can be prevented in persons susceptible to the diseases and PAH patients can be treated by administering an effective dose of a leukotriene inhibitor. Suitable inhibitors include leukotriene Ahydrolase (LTAH) inhibitors, leukotriene Breceptor (BLT1/BLT2) antagonists, 5-lipoxygenase (5-LO) inhibitors, and 5-lipoxygenase activating protein (FLAP) inhibitors.

Growing community of inventors

Palo Alto, CA, United States of America

Mark R Nicolls